New insights for drug resistance in metastatic castration-resistant prostate cancer

Abstract

Prostate cancer is the most common cancer and is the second leading cause of cancer-related deaths among men in the United States. Androgen deprivation therapy (ADT) is the standard treatment for advanced-stage prostate cancer; however, this treatment eventually fails, leading to an incurable disease subtype known as metastatic castration-resistant prostate cancer (mCRPC). There are several molecular mechanisms that facilitate the development of mCRPC engaging androgen receptor (AR) growth axis, including AR amplification, gain of function AR mutations, and AR splice variants that are constitutively active and are a foremost factor for mCRPC development. AR-independent mechanisms with exceptionally low or absent AR expression found in cancer cells suppress ADT effectiveness and contribute to aggressive variants, including neuroendocrine differentiation. Several other AR regulatory factors such as epigenetic modification(s), and DNA damage response have been reported during post-ADT exposure and play a crucial role in mCRPC development. Therefore, targeting prostate cancer cells before their progression to mCRPC would improve patient outcomes. This special issue in “Cancer Drug Resistance” focuses on understanding the mechanism(s) and development of mCRPC resistance. This special issue also highlights the therapeutic strategies to combat against resistant subtype. This issue comprehensively reviews the mCRPC and delivers the update in the forum of mCRPC resistance development.

Keywords

Castration-resistant prostate cancer / drug resistance / cancer stem cells / androgen receptor / neuroendocrine differentiation / extracellular vesicles / chemotherapy / androgen receptor

References

[1] van Dessel LF,Smits M.The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.Nat Commun2019;10:5251 PMCID:PMC6868175

[2] Lavallee L,Saad F.Real-world management of metastatic castration-resistant prostate cancer (mCRPC): a national multicenter cohort study.JCO2022;40:252-252

[3] Huang X,Figg WD.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.J Hematol Oncol2012;5:35 PMCID:PMC3425086

[4] Nuhn P,Fizazi K.Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology.Eur Urol2019;75:88-99

[5] Peyraud F.Combined PARP inhibition and immune checkpoint therapy in solid tumors.Cancers (Basel)2020;12:1502 PMCID:PMC7352466

[6] Yehya A,Zahwe A.Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.Cancer Drug Resist2022;5:667-90

[7] Kumar A,Sharma M.Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells.Cancer Drug Resist2022;5:612-24

[8] Kushwaha PP,Kumar S.Role of prostate cancer stem-like cells in the development of antiandrogen resistance.Cancer Drug Resist2022;5:459-71 PMCID:PMC9255247

[9] Choi WW,Lin J.ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer.Cancer Drug Resist2022;5:165-70 PMCID:PMC8992592

[10] Khalil MI.Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance.Cancer Drug Resist2022;5:93-101 PMCID:PMC8992593

[11] Biersack B,Höpfner M.HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.Cancer Drug Resist2022;5:64-79 PMCID:PMC8992583